drugset / Trial / NCT07089888

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888

Phase 3 Recruiting 250 enrolled Crystalys Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with tophaceous gout.

Timeline

Start
2025-08-04
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule Oral
Subject Dotinurad Small molecule 4 mg Oral

Indications